Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China

Fineline Cube Oct 25, 2024

NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...

Company Deals

HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy

Fineline Cube Oct 25, 2024

HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...

Company Deals

Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies

Fineline Cube Oct 24, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...

Company Drug

Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain

Fineline Cube Oct 24, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco

Fineline Cube Oct 24, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab

Fineline Cube Oct 24, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...

Company Drug

Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy

Fineline Cube Oct 24, 2024

Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Fineline Cube Oct 24, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Policy / Regulatory

NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines

Fineline Cube Oct 24, 2024

The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...

Company Deals

Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004

Fineline Cube Oct 23, 2024

Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...

Company

Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials

Fineline Cube Oct 23, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

LINDIS Biotech’s Catumaxomab Receives Positive Opinion from EMA’s COMP for Malignant Ascites Treatment

Fineline Cube Oct 23, 2024

LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...

Policy / Regulatory

China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products

Fineline Cube Oct 23, 2024

The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...

Company Deals

Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development

Fineline Cube Oct 23, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...

Company Medical Device

China Grand Pharmaceutical Receives NMPA Approval for Innovative Adjustable Thrombectomy Stent

Fineline Cube Oct 23, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...

Company Deals Drug

Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury

Fineline Cube Oct 23, 2024

Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...

Policy / Regulatory

Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines

Fineline Cube Oct 23, 2024

The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...

Company Drug

Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections

Fineline Cube Oct 23, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...

Company Medical Device

German Endoscope Maker KARL STORZ Secures Marketing Approval for Disposable Ureteroscope in China

Fineline Cube Oct 23, 2024

KARL STORZ SE & Co. KG, a leading German endoscope manufacturer, has announced that it...

Company Drug

LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review

Fineline Cube Oct 23, 2024

LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...

Posts pagination

1 … 302 303 304 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.